INSP Inspire Medical Systems, Inc.

QT69

Latest market price

62.56

-4.65-6.92%

Overview Short InterestFilings

INSPQT69Inspire Medical Systems, Inc.·NYSE

Overview Short InterestFilings

62.56-6.92%

Filing

Down 6.9% — Filed an 8-K material-event report (2026-11-02) — details in the filing.

Medium confidence

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

ESTA+0.81%$61.57 UFPT+0.03%$284.06 BFLY+3.68%$6.37 TMDX+0.39%$66.93 NVCR+1.29%$13.38 NEOG+1.73%$12.02 CNMD+0.31%$46.73 TNDM-1.57%$18.38

Snapshot

Index	—	P/E	14.55	EPS (ttm)	4.62	Insider Own	2.40%	Shs Outstand	28.91M	Perf Week	-5.35%

Market Cap	1.94B	Forward P/E	45.62	EPS next Y	1.47	Insider Trans	-0.72%	Shs Float	27.26M	Perf Month	-3.94%

Enterprise Value	1.65B	PEG	0.55	EPS next Q	—			Short Float	16.48%	Perf Quarter	4.79%

Income	135.00M	P/S	2.16	EPS this Y	-26.36%			Short Ratio	5.60	Perf Half Y	22.56%

Sales	900.00M	P/B	2.35	EPS next Y	18.91%	ROA	14.58%	Short Interest	4.49M	Perf YTD	-27.13%

Book/sh	28.57	P/C	6.05	EPS next 5Y	26.37%	ROE	17.62%	52W High	147.03 -57.45%	Perf Year	-8.02%

Cash/sh	11.10	P/FCF	16.61	EPS past 3/5Y	—	ROIC	6.33%	52W Low	38.91 60.78%	Perf 3Y	-55.03%

Dividend Est.	—	EV/EBITDA	19.89	Sales past 3/5Y	30.75% 51.31%	Gross Margin	86.13%	Volatility	3.50% 3.69%	Perf 5Y	-74.22%

Dividend TTM	—	EV/Sales	1.83	EPS Y/Y TTM	167.30%	Oper. Margin	6.02%	ATR (14)	2.82	Perf 10Y	—

Dividend Ex-Date	Jan 09, 2008	Quick Ratio	6.16	Sales Y/Y TTM	4.53%	Profit Margin	15.03%	RSI (14)	43.17	Recom	2.57

Dividend Gr. 3/5Y	—	Current Ratio	8.55	EPS Q/Q	-63.16%	SMA20	-3.62%	Beta	0.63	Target Price	63.00

Payout	0.00%	Debt/Eq	0.04	Sales Q/Q	-7.37%	SMA50	-2.15%	Rel Volume	1.43	Prev Close	67.21

Employees	1,333	LT Debt/Eq	0.04	Earnings	Feb 10	SMA200	15.03%	Avg Volume	751.69K	Price	62.56

IPO Date	May 03, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	60.90% —	Net Debt/EBITDA	-3.52	Volume	1,075,926	Change	-6.92%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-13-26	Reiterated	Mizuho Securities	Outperform	$65 → $75
Oct-06-26	Initiated	Barclays	Underweight	$65
Oct-01-26	Reiterated	RBC Capital	Sector Perform	$60 → $75
Sep-11-26	Reiterated	Stifel Nicolaus	Buy	$75 → $80
Aug-04-26	Reiterated	RBC Capital	Sector Perform	$45 → $60
Aug-04-26	Reiterated	Stifel Nicolaus	Buy	$65 → $75
Aug-04-26	Reiterated	Robert W. Baird		$54 → $59
Aug-04-26	Reiterated	Evercore ISI Group	In Line	$40 → $54
Aug-04-26	Reiterated	Piper Sandler	Neutral	$55 → $60
Aug-04-26	Upgrade	Oppenheimer	Perform → Outperform	$175 → $85

Latest News· Times ET

Nov-02-26

Nov-02-2611:58PM

Inspire Medical Systems, Inc. (INSP) Q3 2026 Earnings Call Transcriptseekingalpha.com

10:14PM

Inspire Medical Systems Q3 Earnings Call Highlightsmarketbeat.com

08:01PM

Here's What Key Metrics Tell Us About Inspire (INSP) Q3 Earningszacks.com

06:10PM

Inspire Medical Systems (INSP) Q3 Earnings and Revenues Beat EstimatesYahoo

04:28PM

Inspire Medical Systems, Inc. Announces Third Quarter 2026 Financial Resultsglobenewswire.com

Oct-26-26

Oct-26-2602:22PM

3 healthcare stocks we keep off our radarYahoo

Oct-23-26

Oct-23-2612:41PM

INSP Stock Gains 47.8% in Three Months: What's Driving the Rally?zacks.com

Oct-19-26

Oct-19-2609:00AM

Here's How Tempus AI Demonstrates Improving Operating LeverageYahoo

Oct-14-26

Oct-14-2609:31AM

Truist Securities Maintains Hold on Inspire Medical Systems, Raises Price Target to $78Benzinga

Oct-09-26

Oct-09-2608:02PM

Inspire Medical Systems Inc (INSP) Stock Up 3.3% and Still Undervalued -- GF Score: 64/100gurufocus.com

Oct-08-26

Oct-08-2604:00AM

3 Cash-Heavy Stocks We Steer Clear OfYahoo

Oct-07-26

Oct-07-2602:00AM

Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRCgurufocus.com

Oct-05-26

Oct-05-2604:05PM

Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026globenewswire.com

12:55PM

Inspire Medical Gains New CPT Codes for Hypoglossal Nerve Stimulationzacks.com

Oct-04-26

Oct-04-2601:44PM

Inspire Medical (INSP): How Much Optimism Is Baked Into This Medtech Stock?Yahoo

Company

Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	900	912	803	625	—	—	—	—	—
Cost of Goods Sold Incl. D&A	125	133	123	97	—	—	—	—	—
Gross Profit	774	779	680	528	—	—	—	—	—
Selling, General and Administrative Excl. Other	620	625	530	452	—	—	—	—	—
Research and Development	100	103	114	117	—	—	—	—	—
Other Operating Expense	0	0	0	-1	—	—	—	—	—
Operating Income	54	51	36	-40	—	—	—	—	—
Interest Expense	0	0	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	16	15	22	20	—	—	—	—	—
Net Income Before Taxes	69	66	58	-20	—	—	—	—	—
Income Taxes	-65	-80	5	1	—	—	—	—	—
Consolidated Net Income	135	145	54	-21	—	—	—	—	—
Net Income From Continuing Operations	135	145	54	-21	—	—	—	—	—
Net Income	135	145	54	-21	—	—	—	—	—
EPS (Recurring)	4.66	4.95	1.80	-0.72	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	4.66	4.95	1.80	-0.72	—	—	—	—	—
EPS (Diluted)	4.62	4.89	1.75	-0.72	—	—	—	—	—
EBITDA	83	80	65	-17	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	13.54	18.86	105.93	—	—	—	—	—	—
Price To Sales Ratio	2.02	2.93	6.93	9.44	—	—	—	—	—
Gross Margin	86.00	85.42	84.68	84.48	—	—	—	—	—
Operating Margin	6.00	5.59	4.48	-6.40	—	—	—	—	—
Net Margin	15.00	15.90	6.72	-3.36	—	—	—	—	—
Shares Outstanding	29	29	30	29	—	—	—	—	—
Market Capitalization	1,814	2,675	5,561	5,899	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kelly Jason P	Officer	Aug 07 '26	Sale	59.55	963	57,347	18,985	Aug 11
Rondoni John	Officer	May 15 '26	Sale	43.28	2,641	114,302	27,165	May 19
Rondoni John	Officer	May 14 '26	Sale	43.01	700	30,107	29,806	May 15
mcCormick Shawn	Director	May 08 '26	Sale	45.31	696	31,536	27,712	May 11
Rondoni John	Officer	Jan 09 '26	Sale	100.00	109	10,900	13,797	Jan 12
mcCormick Shawn	Director	Dec 02 '25	Sale	139.00	1,200	166,800	24,846	Dec 04
mcCormick Shawn	Director	Nov 28 '25	Sale	127.48	2,000	254,960	26,046	Dec 01
Curet Myriam	Director	Aug 08 '25	Sale	77.28	4	309	3,365	Nov 24
Curet Myriam	Director	May 08 '25	Sale	153.22	2	306	3,369	Nov 24
Curet Myriam	Director	Apr 07 '25	Buy	148.26	1	148	3,371	Nov 24
Curet Myriam	Director	Mar 20 '25	Buy	163.84	4	655	3,370	Nov 24
Buchholz Richard	Chief Financial Officer	Aug 29 '25	Sale	93.39	11,000	1,027,290	44,867	Sep 02
Buchholz Richard	Chief Financial Officer	Aug 19 '25	Option Exercise	62.74	25,008	1,569,031	61,247	Aug 21
mcCormick Shawn	Director	Jun 04 '25	Option Exercise	16.00	4,000	64,000	28,046	Jun 06
Rondoni John	Officer	May 19 '25	Sale	149.38	1,734	259,025	13,766	May 21

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.